Pharmacies throughout England have begun providing complimentary meningitis B vaccination as part of a public health response to a recent outbreak. The campaign targets approximately one million young people, including 17 and 18-year-olds in sixth form, as well as students under age 25 enrolling in residential university or further education settings for the first time in autumn 2026.
The vaccination initiative follows an outbreak in Kent that resulted in 29 confirmed or suspected cases and two deaths. Health officials have characterized the situation as unprecedented and explosive. Research indicates that first-year university students face approximately seven times higher risk of meningitis infection compared to peers not attending university, attributed to increased social mixing and shared living arrangements. The virus spreads through close contact such as kissing, sharing beverages or vaping devices, and proximity in communal housing.
The meningitis B vaccine is administered in two doses administered at least 28 days apart, with both doses required for optimal protection. Common side effects include mild fever, nausea, headache, muscle aches, and localized injection site reactions, typically resolving within one to two days. The vaccine contains no live bacteria and cannot cause meningitis. More serious adverse effects remain rare. Eligible individuals can book appointments at participating high street pharmacies beginning July 13, with first appointments available from July 20.
Meningitis B infection poses serious health risks including inflammation of the brain’s protective lining and sepsis, potentially causing permanent disabilities such as hearing loss, amputations, and cognitive damage, or proving fatal in some cases. The vaccine was incorporated into the UK’s routine childhood immunization program for infants born on or after July 1, 2015, which is why older teenagers and young adults previously lacked this protection.
Scientific research suggests the MenB vaccine may not prevent person-to-person transmission, does not protect against all bacterial B strain variations, and may not provide indefinite protection. Nevertheless, UK vaccine experts are recommending routine administration to all teenagers around age 15, with final decisions resting with government officials in each nation. Currently, a separate MenACWY vaccine targeting different meningococcal strains is routinely offered to 14-year-olds.